BRIDGEWATER, N.J. and CAESAREA, Israel — September 23, 2026
Theranica announced peer-reviewed results from a study evaluating its Your Day Ahead artificial intelligence feature, which forecasts next-day migraine likelihood using longitudinal patient-reported data collected through the Nerivio app. The study analyzed 770,473 daily reports from 53,065 Nerivio users between January 2020 and July 2025, making it one of the largest datasets evaluated for next-day migraine forecasting. The best-performing machine-learning model achieved 91.2% precision, 81.0% accuracy, 80.0% sensitivity, 83.0% specificity and an area under the curve (AUC) of 0.893. The findings were published in Neurology Open Access and suggest that an individual’s longer-term headache pattern may provide substantial information for estimating next-day migraine risk.
Longitudinal Headache Patterns Drive Prediction Model
The analysis found that headache patterns recorded during the preceding 30 days contributed more strongly to the prediction model than traditional prodromal symptoms. Researchers evaluated seven machine-learning algorithms using diary entries, pre-treatment questionnaires, demographic information and location-based weather conditions. A customized XGBoost classifier produced the strongest performance, with the relative contribution of features calculated from the 30 days preceding an attack reported at 56.3%, while prodromal symptoms contributed 11.1%. The strongest individual signal was the patient’s rolling average headache severity during the preceding month. The model’s performance did not differ significantly between female and male participants or between adults and adolescents in the analyzed dataset. The authors noted that the forecasted outcome included mild as well as moderate and severe headache pain.
Your Day Ahead Adds Forecasting to Nerivio App
Your Day Ahead is incorporated into the Nerivio app to provide patients with information about their anticipated next-day migraine likelihood. The feature is intended to help users plan around a potential attack and consider practical measures such as maintaining sleep, nutrition and daily routines while continuing their prescribed treatment plan. Theranica states that the feature does not diagnose migraine or recommend changes to prescribed treatment, including preemptive medication use. Nerivio is an FDA-cleared prescription Remote Electrical Neuromodulation (REN) device indicated for acute and/or preventive treatment of migraine with or without aura in patients aged 8 years and older. The company describes Your Day Ahead as an additional digital capability that uses patient-generated data without requiring a separate drug therapy
Advertisement
Study Supports Further Evaluation of AI-Based Migraine Forecasting
The researchers concluded that next-day migraine risk can be forecast using longitudinal patient-reported information, while also identifying limitations that require further validation. The dataset consisted of users of a single therapeutic device and included a population that the study authors characterized as skewed toward frequent, treatment-engaged patients. As a result, the findings may not directly represent all people living with migraine, and broader populations will be needed to assess how well the model generalizes outside the Nerivio user base. Theranica is also pursuing applications of its Remote Electrical Neuromodulation platform beyond migraine and into other chronic pain conditions. The study adds evidence to the emerging use of machine learning and longitudinal patient-generated data for migraine forecasting while highlighting the need for validation across broader clinical populations.
Source :Theranica press release
